Synergistic activities of MET/RON inhibitor BMS-777607 and mTOR inhibitor AZD8055 to polyploid cells derived from pancreatic cancer and cancer stem cells

Molecular Cancer Therapeutics

Volumn 13, Issue 1, 2013, Pages 37-48

  Zeng, Jun Ying ^a,b   Sharma, Sharad ^a   Zhou, Yong Qing ^c   Yao, Hang Ping ^d   Hu, Xing ^b   Zhang, Ruiwen ^a   Wang, Ming Hai ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b HUAIHUA UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AURORA B KINASE; AZD 8055; BARASERTIB; BMS 777067; CISPLATIN; CYCLIN B; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; METHOTREXATE; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTEUR D ORIGINE NANTAIS; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

8N CHROMOSOME; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIVITY; CHROMOSOME; DNA CONTENT; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; PANCREAS CANCER; POLYPLOIDY; PRIORITY JOURNAL;

AMINOPYRIDINES; APOPTOSIS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; MORPHOLINES; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; POLYPLOIDY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDONES; SIGNAL TRANSDUCTION;

EID: 84892619131     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0242     Document Type: Article

References (40)

1. Wang MH, Lee W, Luo YL, Weis MT, Yao HP. Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumorigenic phenotypes in thyroid cancer cells. J Pathol 2007;213:402-11.
2. Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, et al. Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3- kinase and reduces metastasis in human colon carcinoma. J Biol Chem 2009;284:10912-22.
3. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, et al. Shortform ron promotes spontaneous breast cancer metastasis through interaction with phosphoinositide 3-kinase. Genes Cancer 2011;2: 753-62.
4. Logan-Collins J, Thomas RM, Yu P, Jaquish D, Mose E, French R, et al. Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers. Cancer Res 2010;70:1130-40.
5. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 2007;67:6075-82.
6. Camp ER, Yang A, Gray MJ, Fan F, Hamilton SR, Evans DB, et al. Tyrosine kinase receptor RON in human pancreatic cancer: expression, function, and validation as a target. Cancer 2007;109:1030-9.
7. O'Toole JM, Rabenau KE, Burns K, Lu D, Mangalampalli V, Balderes P, et al. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 2006;66:9162-70.
8. Hidalgo M. Pancreatic cancer. New Engl J Med 2010;362:1605-17.
9. Yu PT, Babicky M, Jaquish D, French R, Marayuma K, Mose E, et al. The RON-receptor regulates pancreatic cancer cell migration through phosphorylation-dependent breakdown of the hemidesmosome. Int J Cancer 2012;131:1744-54.
10. Zhao S, Ammanamanchi S, Brattain M, Cao L, Thangasamy A, Wang J, et al. Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells. J Biol Chem 2008;283:11293-301.
11. Tactacan CM, Chang DK, Cowley MJ, Humphrey ES, Wu J, Gill AJ, et al. RON is not a prognostic marker for resectable pancreatic cancer. BMC Cancer 2012;12:395-404.
12. Moser C, Lang SA, Hackl C, Zhang H, Lundgren K, Hong V, et al. Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors. Anticancer Res 2012;32:427-37.
13. Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R, Wang MH. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm 2011;8:2310-9.
14. Zhang Y, Kaplan-Lefko PJ, Rex K, Yang Y, Moriguchi J, Osgood T, et al. Identification of a novel recepteur d'origine nantais/c-met smallmolecule kinase inhibitor with antitumor activity in vivo. Cancer Res 2008;68:6680-7.
15. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Metdependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003;63:7345-55.
16. Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LA, et al. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)- 4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2 dihy-dropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2009;52:1251-4.
17. Sharma S, Zeng ZJ, Zhuang CM, Zhou YQ, Yao HP, Hu X, et al. Smallmolecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther 2013;12:725-36.
18. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 2007;14:3629-37.
19. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 2011;6:e20636-42.
20. Yoshikawa W, Hara H, Takehara T, Shimonishi M, Sakai H, Shimizu N, et al. Characterization of free alpha- and beta-chains of recombinant macrophage-stimulating protein. Arch Biochem Biophys 1999;363: 356-60.
21. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W, et al. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 2006;5:1179-86.
22. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATPcompetitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98.
23. Tovar C, Higgins B, Deo D, Kolinsky K, Liu JJ, Heimbrook DC, et al. Small-molecule inducer of cancer cell polyploidy promotes apoptosis or senescence: implications for therapy. Cell Cycle 2010;9:3364-75.
24. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triplenegative breast cancers through paracrine activation of Met. Breast Cancer Res 2012;14:104-13.
25. Wang D, Shen Q, Xu XM, Chen YQ, Wang MH. Activation of the RON receptor tyrosine kinase attenuates transforming growth factor-beta1- induced apoptotic death and promotes phenotypic changes in mouse intestinal epithelial cells. Carcinogenesis 2005;26:27-36.
26. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, et al. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Clin Cancer Res 2007; 13:3682-8.
27. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATPcompetitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98.
28. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008;118:3065-74.
29. Moore SF, Hunter RW, Hers I. mTORC2 protein complex-mediated Akt (protein kinase B) Serine 473 phosphorylation is not required for Akt1 activity in human platelets [corrected]. J Biol Chem 2100;286: 24553-60.
30. Liu D, Lampson MA. Regulation of kinetochore-microtubule attachments by Aurora B kinase. Biochem Soc Trans 2009;37:976-80.
31. Yao HP, Zhou YQ, Ma Q, Guin S, Padhye SS, Zhang RW, et al. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells. Mol Cancer 2111;10:82.
32. Dai Y, Bae K, Pampo C, Siemann DW. Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation. Clin Exp Metastasis 2012;29:253-61.
33. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010;9: 1554-61.
34. Adams RR, Carmena M, Earnshaw WC. Chromosomal passengers and the (aurora) ABCs of mitosis. Trends in Cell Biology 2001;11: 49-54.
35. Tao Y, Leteur C, Calderaro J, Girdler F, Zhang P, Frascogna V, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle 2009; 8:3172-81.
36. Prencipe M, Fitzpatrick P, Gorman S, Tosetto M, Klinger R, Furlong F, et al. Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro. Br J Cancer 2009;101: 1900-8.
37. Wang Q, Wu PC, Dong DZ, Ivanova I, Chu E, Zeliadt S, et al. Polyploidy road to therapy-induced cellular senescence and escape. Int J Cancer 2013;132:1505-15.
38. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
39. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
40. Shor B, Gibbons JJ, Abraham RT, Yu K. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009;8:3831-7.